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Two decades ago, Devereux and Alderman (1) suggested
that pre-clinical diseases such as left ventricular hypertrophy,
vascular hypertrophy, coronary, carotid, and peripheral
atherosclerosis, as well as renal dysfunction are the initial
steps on the pathway to clinical events such as myocardial
infarction, stroke, and sudden cardiac death. Since then,
there has been extensive research evaluating the importance
of identifying markers of subclinical target organ damage to
prevent the well-known clinical manifestations of cardio-
vascular disease. Consequently, guidelines put more and
more emphasis on the importance of detecting subclinical
cardiovascular disease, to risk stratify and guide the clinical
management of patients at risk for cardiovascular morbidity
and mortality. However, a question that is not clear from
guidelines is whether atrial ﬁbrillation should be considered
as (subclinical) target organ damage or frank disease (clinical
endpoint).See page 2007Although the phenotype presentation of atrial ﬁbrillation
may have many causes, the most common etiology in the
Western world is hypertensive heart disease, caused by the
high prevalence of hypertension. In addition, both patients
groups with either lone hypertension or lone atrial ﬁbrilla-
tion have high risk of developing either atrial ﬁbrillation or
hypertension, respectively, during follow-up (2). The patho-
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Guest Editor for this paper.and function that are predictive of atrial ﬁbrillation. In
addition, we have shown that reduction in left atrial size
(3) and ventricular hypertrophy (4) in hypertensive patients
leads to signiﬁcant reduction in incident atrial ﬁbrillation
and stroke. This has led us to propose that atrial ﬁbrillation
may not be solely a disease entity with disorders in the
electrical system on the cellular level (5). In fact, an impaired
hemodynamic status attributable to just high normal blood
pressure or frank hypertension may be the major driving
factor for development of atrial ﬁbrillation. A report from
2009 in this Journal (6) suggested that improvement in the
hemodynamic status does reduce the risk of new-onset atrial
ﬁbrillation. Belluzzi et al. (6) treated nonhypertensive pa-
tients with lone atrial ﬁbrillation with ramipril or placebo and
found more than 3-fold increased risk of incident atrial
ﬁbrillation in those treated with placebo as well as less
incident hypertension in those treated with ramipril versus
placebo.
In this issue of the Journal, Chrispin et al. (7) present ana-
lyses from theMESA (Multi-Ethnic Study of Atherosclerosis)
trial. A large cohort of subjects (n ¼ 4,942) without clinically
recognized cardiovascular disease underwent cardiac magnetic
resonance imaging and electrocardiographic examination at
baseline. Indeed, MESA was designed to investigate the
progression of subclinical cardiovascular disease to clinical
events. As part of MESA, patients were screened for the
development of atrial ﬁbrillation during an average 6.9-year
follow-up. The investigators tested several standard electro-
cardiographic criteria of left ventricular hypertrophy in their
capability of reﬁning risk prediction for atrial ﬁbrillation. In
this study, patients with and without atrial ﬁbrillation had
prevalences of hypertension in 34% and 57% of cases,
respectively. The average blood pressure in those without atrial
ﬁbrillation was 125 mm Hg, whereas it was on average
135 mm Hg in those with atrial ﬁbrillation. Therefore, more
than one-half of patients inMESA have blood pressure within
the normal range, suggesting a strong relationship between the
risk of atrial ﬁbrillation and blood pressure in the high normal
range. Thus, these data give us important insight into the
importance of subclinical cardiovascular disease for prediction
of atrial ﬁbrillation in patients with normal to low blood
pressure.
In addition, the current study from MESA adds to in-
formation about left ventricular hypertrophy measured by
cardiac magnetic resonance imaging. This is important as
cardiac magnetic resonance imaging is considered the gold
standard for determination of anatomic left ventricular mass
and volumes. In a letter to the editor, de Simone and
Devereux (8) point out limitations of cardiac magnetic
resonance imaging, including use of machines with low
magnetic ﬁeld, low spatial resolution, and low slice thickness,
in addition to use of higher magnetic ﬁelds (3 T) are re-
commended for cardiac magnetic resonance imaging (9). In
the current study, measurements were taken with a 0.6-cm
slice thickness followed by a 0.4-cm gap; gating issues may
have offset true end-diastolic measures; and endocardial and
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2015epicardial contour tracings may not have been standardized
exactly at the papillary muscle tips, all of which affect the
determination of left ventricular mass. These pitfalls might be
especially aggravated by the intrinsic difﬁculties of magnetic
resonance imaging in detecting (and reproducing) the largest
left ventricular minor axis, because of slice thickness and
difﬁculty in aligning acquisitions in near-perfect orthogonal
planes with left ventricular structures. These limitations can
be offset by echocardiography, using orthogonal images or,
especially, long axis with precise anatomic markers (8). Thus,
technical limitations may be 1 of several reasons why both
cardiac magnetic resonance imaging and electrocardiographic
measurements of left ventricular hypertrophy can remain in
the samemodel predicting atrial ﬁbrillation without toomuch
collinearity. However, just as important, this may also be
because even though cardiac magnetic resonance imaging
may be more reproducible than the electrocardiogram, elec-
trical and anatomical left ventricular hypertrophy might
convey different information on cardiac structure and func-
tion (10), and thus risk of future atrial ﬁbrillation. This hy-
pothesis is supported by the current study by Chrispin et al.
(7), as they show that electrocardiographic left ventricular
hypertrophy has prognostic importance independent of the
left ventricular geometrical evaluation by cardiac magnetic
resonance imaging. Thus, the study would have been
strengthened by receiver-operating characteristic and net
reclassiﬁcation improvement analyses for evaluation of
whether cardiac magnetic resonance imaging and electro-
cardiographic left ventricular hypertrophy add incremental to
the prediction of atrial ﬁbrillation (11).
Limitations of the current study are inherent to the
diagnosis of atrial ﬁbrillation that was made according
to International Classiﬁcation of Diseases-Ninth Revision
codes only. Most likely, the incidence of atrial ﬁbrillation is
underestimated when compared with that of patients who
were followed using noninvasive or invasive electrocardio-
graphic measurements that were read at an electrocardio-
graphic core laboratory. This also leads to nondiscrimination
of paroxysmal, persistent, and permanent atrial ﬁbrillation.
This is especially important as the clinical value of atrial
ﬁbrillation as subclinical target organ damage or frank
clinical disease may depend on length of time in atrial
ﬁbrillation, which may be inaccurately estimated due to the
paroxysmal nature of atrial ﬁbrillation.
The clinical implications of the study by Chrispin et al. (7)
is that pre-clinical target organ damage as left ventricular
hypertrophy in normotensive subjects without clinically
evident cardiovascular disease is detected in approximatelyone-half of participants. These ﬁndings lead to the conclusion
that blood pressure and left ventricular hypertrophy should be
targets of treatment, even in subjects with subclinical car-
diovascular disease, to prevent atrial ﬁbrillation as is shown in
patients with more-established disease. This argues that atrial
ﬁbrillation is in fact target organ damage that should lead the
clinician to initiate reducing the patient’s cardiovascular risk
factors and perhaps also initiate medical treatment with
afterload reducing therapy even in the presence of normal
brachial blood pressures.
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